FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767179430> ?p ?o ?g. }

• W2767179430 endingPage "240" @default.
• W2767179430 startingPage "234" @default.
• W2767179430 abstract "Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those in patients who maintained treatment with INF or SB2. Methods Patients with moderate to severe RA despite methotrexate treatment were randomised (1:1) to receive SB2 or INF at weeks 0, 2 and 6 and every 8 weeks thereafter until week 46. At week 54, patients previously receiving INF were rerandomised (1:1) to switch to SB2 (INF/SB2 (n=94)) or to continue on INF (INF/INF (n=101)) up to week 70. Patients previously receiving SB2 continued on SB2 (SB2/SB2 (n=201)) up to week 70. Efficacy, safety and immunogenicity were assessed up to week 78. Results Efficacy was sustained and comparable across treatment groups. American College of Rheumatology (ACR) 20 responses between weeks 54 and 78 ranged from 63.5% to 72.3% with INF/SB2, 66.3%%–69.4% with INF/INF and 65.6%–68.3% with SB2/SB2. Treatment-emergent adverse events during this time occurred in 36.2%, 35.6% and 40.3%, respectively, and infusion-related reactions in 3.2%, 2.0% and 3.5%. Among patients who were negative for antidrug antibodies (ADA) up to week 54, newly developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and SB2/SB2 groups, respectively. Conclusions The efficacy, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2. Trial registration number NCT01936181; EudraCT number: 2012-005733-37." @default.
• W2767179430 created "2017-11-10" @default.
• W2767179430 creator A5009243219 @default.
• W2767179430 creator A5013697089 @default.
• W2767179430 creator A5017320787 @default.
• W2767179430 creator A5020978466 @default.
• W2767179430 creator A5028826874 @default.
• W2767179430 creator A5050458041 @default.
• W2767179430 creator A5054896185 @default.
• W2767179430 creator A5058023435 @default.
• W2767179430 creator A5058755659 @default.
• W2767179430 creator A5058833374 @default.
• W2767179430 creator A5065723883 @default.
• W2767179430 creator A5070999679 @default.
• W2767179430 creator A5082439787 @default.
• W2767179430 creator A5089382889 @default.
• W2767179430 creator A5090753435 @default.
• W2767179430 date "2017-10-17" @default.
• W2767179430 modified "2023-10-17" @default.
• W2767179430 title "Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study" @default.
• W2767179430 cites W1954244899 @default.
• W2767179430 cites W2113633952 @default.
• W2767179430 cites W2121050884 @default.
• W2767179430 cites W2126525702 @default.
• W2767179430 cites W2151444904 @default.
• W2767179430 cites W2156899784 @default.
• W2767179430 cites W2174460595 @default.
• W2767179430 cites W2203977709 @default.
• W2767179430 cites W2293590090 @default.
• W2767179430 cites W2342464058 @default.
• W2767179430 cites W2401357881 @default.
• W2767179430 cites W2407658018 @default.
• W2767179430 cites W2415679102 @default.
• W2767179430 cites W2543281533 @default.
• W2767179430 cites W2567453335 @default.
• W2767179430 cites W2584947097 @default.
• W2767179430 cites W2610308940 @default.
• W2767179430 cites W2613299853 @default.
• W2767179430 cites W2624289061 @default.
• W2767179430 cites W2736727076 @default.
• W2767179430 doi "https://doi.org/10.1136/annrheumdis-2017-211741" @default.
• W2767179430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5867419" @default.
• W2767179430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29042358" @default.
• W2767179430 hasPublicationYear "2017" @default.
• W2767179430 type Work @default.
• W2767179430 sameAs 2767179430 @default.
• W2767179430 citedByCount "98" @default.
• W2767179430 countsByYear W27671794302017 @default.
• W2767179430 countsByYear W27671794302018 @default.
• W2767179430 countsByYear W27671794302019 @default.
• W2767179430 countsByYear W27671794302020 @default.
• W2767179430 countsByYear W27671794302021 @default.
• W2767179430 countsByYear W27671794302022 @default.
• W2767179430 countsByYear W27671794302023 @default.
• W2767179430 crossrefType "journal-article" @default.
• W2767179430 hasAuthorship W2767179430A5009243219 @default.
• W2767179430 hasAuthorship W2767179430A5013697089 @default.
• W2767179430 hasAuthorship W2767179430A5017320787 @default.
• W2767179430 hasAuthorship W2767179430A5020978466 @default.
• W2767179430 hasAuthorship W2767179430A5028826874 @default.
• W2767179430 hasAuthorship W2767179430A5050458041 @default.
• W2767179430 hasAuthorship W2767179430A5054896185 @default.
• W2767179430 hasAuthorship W2767179430A5058023435 @default.
• W2767179430 hasAuthorship W2767179430A5058755659 @default.
• W2767179430 hasAuthorship W2767179430A5058833374 @default.
• W2767179430 hasAuthorship W2767179430A5065723883 @default.
• W2767179430 hasAuthorship W2767179430A5070999679 @default.
• W2767179430 hasAuthorship W2767179430A5082439787 @default.
• W2767179430 hasAuthorship W2767179430A5089382889 @default.
• W2767179430 hasAuthorship W2767179430A5090753435 @default.
• W2767179430 hasBestOaLocation W27671794301 @default.
• W2767179430 hasConcept C126322002 @default.
• W2767179430 hasConcept C141071460 @default.
• W2767179430 hasConcept C159654299 @default.
• W2767179430 hasConcept C17991360 @default.
• W2767179430 hasConcept C197934379 @default.
• W2767179430 hasConcept C198451711 @default.
• W2767179430 hasConcept C203014093 @default.
• W2767179430 hasConcept C2777138892 @default.
• W2767179430 hasConcept C2777575956 @default.
• W2767179430 hasConcept C2780868878 @default.
• W2767179430 hasConcept C2781059491 @default.
• W2767179430 hasConcept C59491497 @default.
• W2767179430 hasConcept C71924100 @default.
• W2767179430 hasConcept C90924648 @default.
• W2767179430 hasConceptScore W2767179430C126322002 @default.
• W2767179430 hasConceptScore W2767179430C141071460 @default.
• W2767179430 hasConceptScore W2767179430C159654299 @default.
• W2767179430 hasConceptScore W2767179430C17991360 @default.
• W2767179430 hasConceptScore W2767179430C197934379 @default.
• W2767179430 hasConceptScore W2767179430C198451711 @default.
• W2767179430 hasConceptScore W2767179430C203014093 @default.
• W2767179430 hasConceptScore W2767179430C2777138892 @default.
• W2767179430 hasConceptScore W2767179430C2777575956 @default.
• W2767179430 hasConceptScore W2767179430C2780868878 @default.
• W2767179430 hasConceptScore W2767179430C2781059491 @default.
• W2767179430 hasConceptScore W2767179430C59491497 @default.
• W2767179430 hasConceptScore W2767179430C71924100 @default.

• next